Imatinib Mesylate Tablet, Film Coated
Product Images NDC 42292-043

10 FDA label images from Mylan Institutional Inc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Imatinib Mesylate (NDC 42292-043). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Mylan Institutional Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Imatinib Mesylate Structural Formula (Image 01)

Imatinib Mesylate Structural Formula (Image 01)
Chemical structure diagram of imatinib mesylate, the active ingredient in Imatinib Mesylate tablets. The structure displays molecular bonds and groups including a mesylate moiety.*
FDA Label Image

Progression Free Survival (itt Principle) (Image 02)

Progression Free Survival (itt Principle) (Image 02)
Imatinib Mesylate 100 mg film-coated tablets in a carton label from Mylan Institutional Inc. The label shows the tablet image, dosage strength (100 mg), quantity (30 tablets, 3x10), and includes storage instructions along with manufacturer details from Mylan Pharmaceuticals Inc.*
FDA Label Image

Time To Progression To Ap Or Bc (itt Principle) (Image 03)

Time To Progression To Ap Or Bc (itt Principle) (Image 03)
The image shows the front and back of a blue unit-dose package distributed by Mylan Institutional Inc, Rockford, IL. The package includes warnings that it is not child resistant, intended for institutional use only, and provides light resistance. The back features a small white label with a QR code and placeholders for NDC, expiration date, and lot number. No specific drug strength or name is visible on the package.*
FDA Label Image

Study 1 Recurrence-free Survival (itt Population) (Image 04)

Study 1 Recurrence-free Survival (itt Population) (Image 04)
A Kaplan-Meier survival curve chart comparing the percentage of patients without progression over months since randomization between two groups: Imatinib arm (solid line) and IFN+Ara-C arm (dashed line). The chart includes patient counts at progression and follow-up, as well as a hazard ratio with confidence interval and p-value for the comparison.*
FDA Label Image

Study 2 Recurrence-free Survival (itt Population) (Image 05)

Study 2 Recurrence-free Survival (itt Population) (Image 05)
A survival curve chart comparing the percentage of patients without progression to AP/BC over 72 months since randomization between two treatment arms: Imatinib and IFN+Ara-C. The chart includes hazard ratio statistics and patient numbers for each group, illustrating better progression-free survival in the Imatinib arm.*
FDA Label Image

Study 2 Overall Survival (itt Population) (Image 06)

Study 2 Overall Survival (itt Population) (Image 06)
Imatinib Mesylate 400 mg film-coated tablets packaging label showing oblong, brown tablets imprinted with 'I 400'. The label includes the NDC 42292-044-03, indicates a 30 tablet count (3 x 10), and states that it is Rx only. Storage instructions and manufacturer details for Mylan Pharmaceuticals Inc. are also included.*
FDA Label Image

Imatinib Mesylate 100 mg Tablets Unit Carton Label (Image 07)

Imatinib Mesylate 100 mg Tablets Unit Carton Label (Image 07)
A blue unit-dose packaging label for Imatinib Mesylate tablets distributed by Mylan Institutional Inc., Rockford, IL. The front states the package is not child resistant, for institutional use only, with light-resistant properties and a window for lot number and expiration date. The back displays a white label with a QR code, expiration date, and lot number.*
FDA Label Image

Serialized Unit Carton (Image 08)

Serialized Unit Carton (Image 08)
Imatinib Mesylate unit-dose packaging label in blue with white text. The label includes warnings stating it is not child resistant, intended for institutional use only, and advises keeping the drug out of reach of children. It notes the container provides light resistance and has a see-through window for lot number and expiration date. Distributed by Mylan Institutional Inc., Rockford, IL, USA.*
FDA Label Image

Imatinib Mesylate 400 mg Tablets Unit Carton Label (Image 09)

Imatinib Mesylate 400 mg Tablets Unit Carton Label (Image 09)
Imatinib Mesylate 400 mg film-coated oral tablets packaging label showing two images of an oval tablet engraved with 'I 400'. The label indicates 30 tablets (3 x 10) with NDC 42292-044-03, manufactured by Mylan Pharmaceuticals Inc., Morgantown, WV, and made in Germany. Storage and handling instructions are also included.*
FDA Label Image

Serialized Unit Carton (Image 10)

Serialized Unit Carton (Image 10)
Imatinib Mesylate unit-dose packaging label in blue, distributed by Mylan Institutional Inc. The label includes safety and usage warnings such as not child resistant, for institutional use only, and instructions to keep out of children's reach. It features a window for lot number and expiration date and a QR code on the lower section.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.